Can less radiation be enough? new trial aims to cut side effects for HPV-linked throat cancer
NCT ID NCT02945631
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether a lower dose of chemoradiotherapy, given after initial chemotherapy, can effectively treat locally advanced HPV-positive oropharynx cancer while reducing long-term side effects. The study involves 43 participants and tracks how long the cancer stays under control, overall survival, and toxicity rates. The goal is to find a less harsh treatment option for this specific type of throat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chemoradiotherapy (lower-dose radiation with chemotherapy)
- What this could lead to
- If successful, this could show that a lower dose of chemoradiotherapy is safe and effective for HPV-positive throat cancer, reducing long-term side effects.
- What could go wrong
- This is a small, early-phase trial with only 43 participants, so results may not apply to all patients. The lower dose might not control the cancer as well as standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HPV POSITIVE OROPHARYNX CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States